Medicines recall drug alert issued for potentially contaminated ranitidine products

Medicines recall drug alert issued for potentially contaminated ranitidine products

Last night the government body tasked with regulating drug safety, the Medicines and Healthcare products Regulatory Agency (MHRA), issued a warning to healthcare professionals following an investigation.

The pharma company told Proactive all unexpired stock of four types of the drug was going to be removed from retailers as a "precautionary action" and investigations were ongoing.

The latest move comes just days after the U.S. Food and Drug Administration found "unacceptable' levels of probable cancer-causing impurity in the popular heartburn drug".

Four kinds of Zantac be pleased been recalled by GlaxoSmithKline, the treatment manufacturer, at the side of; 150mg (10ml) Syrup, Zantac 50mg (2ml) Injection, Zantac 150mg Capsules and Zantac 300mg Capsules.

But patients should keep taking their prescribed medicine, officials advise.

Pharmacists and pharmacy teams are required to stop supplying the affected products immediately, and quarantine and return all remaining stock of these products to their supplier using their agreed process.

More news: China Punishes NBA As Crisis Over Democracy Tweet Deepens
More news: Democrats subpoena Sondland for testimony, documents
More news: Doom Eternal delayed to March next year

Anyone who is concerned about taking their medication should speak to their doctor or pharmacist.

The company led-global recall cites possible contamination with an impurity N-nitrosodimethylamine (NDMA) which has genotoxic and carcinogenic potential.

The government agency said it was also investigating other potentially impacted products and will provide further updates as the investigation progresses.

Currently, there is no evidence that medicines containing this type of impurity have caused any harm to patients, say experts. It is present in some foods and in water supplies but is not expected to cause harm when ingested in very low levels.

"We have also requested risk assessments from the relevant companies which will include the testing of potentially affected batches".

GSK, the original developer of the antacid Zantac, in an emailed comment today pointed out that it does not sell Zantac prescription or over-the-counter products in the U.S. Sanofi has U.S. rights to the brand.

Related Articles